Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) EPS (Basic) (2016 - 2025)

Adma Biologics (ADMA) has disclosed EPS (Basic) for 14 consecutive years, with $0.21 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) fell 56.25% year-over-year to $0.21, compared with a TTM value of $0.62 through Dec 2025, down 27.06%, and an annual FY2025 reading of $0.62, down 27.06% over the prior year.
  • EPS (Basic) was $0.21 for Q4 2025 at Adma Biologics, up from $0.15 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.48 in Q4 2024 and bottomed at -$0.16 in Q1 2021.
  • Average EPS (Basic) over 5 years is $0.02, with a median of -$0.03 recorded in 2023.
  • The sharpest move saw EPS (Basic) soared 1400.0% in 2024, then tumbled 56.25% in 2025.
  • Year by year, EPS (Basic) stood at -$0.07 in 2021, then grew by 14.29% to -$0.06 in 2022, then tumbled by 33.33% to -$0.08 in 2023, then surged by 700.0% to $0.48 in 2024, then tumbled by 56.25% to $0.21 in 2025.
  • Business Quant data shows EPS (Basic) for ADMA at $0.21 in Q4 2025, $0.15 in Q3 2025, and $0.15 in Q2 2025.